Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1588-1593

  Horti, J ^a   Dixon, S C ^a   Logothetis, C J ^b   Guo, Y ^a   Reed, E ^a   Figg, W D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AGM 1883; Androgen receptor; Androgen independent prostate cancer; Prostate specific antigen; TNP 470

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; CELL PROTEIN; DRUG METABOLITE; FUMAGILLOL CHLOROACETYLCARBAMATE; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ANGIOGENESIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE MARKER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SECRETION; TRANSCRIPTION REGULATION;

EID: 0033052655     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690253     Document Type: Article

References (27)

1. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M and Takuwa Y (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54: 3407-3412
2. Bauer KS, Dixon SC and Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation with is species-dependent. Biochem Pharmacol 55: 1827-1834
3. Figg WD, Yeh HJC, Thibault A, Pluda JM, Itoh F, Yarchoan R and Cooper MR (1994) Assay of the antiangiogenic compound, TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high performance liquid chromatography in plasma. J Chrom 652: 187-194
4. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E and Sartor O (1996) Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14: 513-517
5. Figg WD, Bergan R, Brawley O, Tompkins A, Linehan M, Duray P, Bauer KS, Pluda J and Reed E (1997a) Randomized phase II study of thalidomide in androgen independent prostate cancer, Proc Am Soc Clin Oncol 16: 1235
6. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E and Yarchoan R (1997b) The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1: 91-97
7. Folkman J and Ingber D (1992) Inhibition of angiogenesis. Semin Cancer Biol 3: 89-96
8. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamary T, Brem H and Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557
9. Inoue K, Korenagea H, Tanaka N, Sakamoto N and Kadoya S (1988) The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydrate Res 181: 135-142
10. Kato T, Sato K, Kakinuma H and Matsuda Y (1994) Enhanced suppression of tumor growth by combination of angiogenesis inhibitorO-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147
11. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M and Fossa SD (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615
12. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D and Folkman J (1991) Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174: 1070-1076
13. Logothetis CJ, Wu K, Jaeckle KA, Amato R, Finn L, Weiss R, Daliani D, Figg WD, Ghaddar H and Gutterman J (1997) Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res (submitted)
14. Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O and Cooper MR (1996) A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann Oncol 7: 939-944
15. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF and Sharpe RJ (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247: 77-79
16. Masiero L, Figg WD and Kohn EC (1997) New anti-angiogenesis agents: review of experience with CAI, thalidomide, TNP-470, and IL-12. Angiogenesis J 1: 23-35
17. Matsubara T, Saura R, Hirohata K and Ziff M (1989) Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 83: 158-167
18. O'Reilly MS, Brem H and Folkman J (1995) Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30: 325-329
19. Sartor O (1995) Prostate-specific antigen changes before and after administration of an angiogenesis inhibitor (TNP-470). Oncol Rep 2: 1101-1102
20. Sridhara R, Eisenberger MA, Sinibaldi V, Reyno LM and Egorin MJ (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13: 2944-2953
21. Taylor S and Folkman J (1982) Protamine is an inhibitor of angiogenesis. Nature 297: 307-312
22. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC and Chung LW (1996) Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794-801
23. Thibault A, Sartor O, Cooper MR, Figg WD and Myers CE (1993) A 75% decline in prostate specific antigen (PSA) predicts survival in hormone refractory prostate cancer. Proc Am Assoc Cancer Res 34: A1143
24. Thorpe PE, Derbyshire FJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang YC and Rao-Bette M (1993) Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res 53: 3000-3007
25. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ and Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586
26. Walls R, Thibault A, Lei L, Wood C, Kozlowsky JM, Figg WD, Sampson ML, Elin RJ and Samid D (1996) The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 29: 177-182
27. Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL Jr and Schellhammer PF (1996) Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 68: 259-264